Marcel Rozario, NP
Acute Care · Medina, NYNPI 1992996912
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,072 and has fallen 92.4% since, to $233 in 2025. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$2K
- GSK$1K
- AbbVie$1K
- Boehringer Ingelheim$985
- Lilly USA, LLC$751
- plus $2K from 17 others
What the payments were for
- Food & beverage$10,034100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $1,923 |
| AstraZeneca | 38 | $1,759 |
| GSK | 58 | $1,233 |
| AbbVie | 30 | $1,068 |
| Boehringer Ingelheim | 40 | $985 |
| Lilly USA, LLC | 56 | $751 |
| Novo Nordisk | 37 | $651 |
| Bayer | 25 | $427 |
| Sanofi-aventis U.S. LLC | 12 | $365 |
| Pfizer | 12 | $182 |
| Mylan Specialty L.p. | 7 | $118 |
| Novartis | 6 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $73 |
| Merck | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $50 |
| Johnson & Johnson | 2 | $31 |
| Lundbeck LLC | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,034 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 172 | $200,961 |
| EliquisApixaban | 133 | $109,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $86,411 |
| TrulicityDulaglutide | 56 | $69,749 |
| RybelsusSemaglutide | 51 | $69,656 |
| FarxigaDapagliflozin Propanediol | 86 | $66,328 |
| MounjaroTirzepatide | 55 | $66,108 |
| OzempicSemaglutide | 54 | $62,068 |
| XareltoRivaroxaban | 61 | $50,206 |
| KerendiaFinerenone | 50 | $37,879 |
| EntrestoSacubitril/Valsartan | 34 | $33,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $23,235 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $19,149 |
| OxycontinOxycodone Hcl | 12 | $18,731 |
| JanuviaSitagliptin Phosphate | 11 | $10,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $985 | $211,171185 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $751 | $135,857111 claims |
| Novo NordiskRybelsus, Ozempic | $651 | $131,724105 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,233 | $118,178202 claims |
| PfizerEliquis | $182 | $109,651133 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,759 | $95,667146 claims |
| Johnson & JohnsonXarelto | $31 | $50,20661 claims |
| BayerKerendia | $427 | $37,87950 claims |
| NovartisEntresto | $118 | $33,34234 claims |
| MerckJanuvia, Janumet | $72 | $19,02222 claims |
| AbbVieLinzess | $1,068 | $6,72912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in Medina
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
- Julie Anne RoldanNew York$10K
- Dana SiscoSuffern$9K
- Alisha MattondoManhasset$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.